Disease · MONDO_0011385
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment vs Placebo: deaths from any cause | 0 of 43 | 0 of 40 | 83 | NCT04272606 | Trial comparisons |
| Treatment vs Placebo: serious adverse events | 0 of 43 | 2 of 40 | 83 | NCT04272606 | Trial comparisons |
| Intradiscal rhGDF-5 (1.0mg) vs Intradiscal rhGDF-5 (2.0mg): Treatment Emergent Adverse Events- Relationship to Study Drug | 2 of 14 | 1 of 26 | 40 | NCT01158924 | Trial comparisons |
| Intradiscal rhGDF-5 (1.0mg) vs Intradiscal rhGDF-5 (2.0mg): serious adverse events | 1 of 14 | 4 of 26 | 40 | NCT01158924 | Trial comparisons |
| Intradiscal rhGDF-5 (1.0mg) vs Intradiscal rhGDF-5 (2.0mg): Neurological Assessment for Motor Function and Reflexes/Sensory | 0 of 13 | 2 of 25 | 38 | NCT01158924 | Trial comparisons |
| Intradiscal rhGDF-5 (0.25mg) vs Intradiscal rhGDF-5 (1.0mg): Neurological Assessment for Motor Function and Reflexes/Sensory | 0 of 7 | 0 of 25 | 32 | NCT00813813 | Trial comparisons |
| Intradiscal rhGDF-5 (0.25mg) vs Intradiscal rhGDF-5 (1.0mg): Treatment Emergent Adverse Events- Relationship to Study Drug | 2 of 7 | 1 of 25 | 32 | NCT00813813 | Trial comparisons |
| Intradiscal rhGDF-5 (0.25mg) vs Intradiscal rhGDF-5 (1.0mg): serious adverse events | 2 of 7 | 2 of 25 | 32 | NCT00813813 | Trial comparisons |
| Intradiscal rhGDF-5 vs Vehicle Control: Treatment Emergent Adverse Events- Relationship to Study Drug | 0 of 22 | 1 of 9 | 31 | NCT01182337 | Trial comparisons |
| Intradiscal rhGDF-5 1.0mg vs Vehicle Control: Treatment Emergent Adverse Events- Relationship to Study Drug | 0 of 22 | 0 of 9 | 31 | NCT01182337 | Trial comparisons |
| Intradiscal rhGDF-5 vs Vehicle Control: serious adverse events | 5 of 22 | 2 of 9 | 31 | NCT01182337 | Trial comparisons |
| Intradiscal rhGDF-5 1.0mg vs Vehicle Control: Neurological Assessment for Motor Function and Reflexes/Sensory | 0 of 21 | 0 of 5 | 26 | NCT01182337 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011385/comparisons